SAN FRANCISCO: WeissComm Partners has added three biotech companies that are preparing to bring their novel therapies to market.
Threshold Pharmaceuticals has retained the agency to build awareness around two therapies that are in phase 3 clinical trials. Its first therapy, for benign prostate enlargement, could treat a potentially large patient population; outreach for its pancreatic cancer treatment would be more targeted.
WeissComm will provide strategic counsel on media and investor relations, in addition to planning road tours and conference calls with Threshold's executives. The agency will also assist with clinical trial recruitment efforts.
WeissComm COO Diane Weiser added that the agency is also exploring potential alliances with advocacy groups that deal with prostate and pancreatic cancer.
Separately, the firm is also working with Iomai, which develops needle-free vaccine technology, and Cardica, whose products are used during heart surgery.